FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to field of medicine and deals with pharmaceutical composition for treating Gaucher disease and method of treatment. Composition contains velaglucerase in effective quantity, citric acid, polysorbate 20, sodium citrate, and sucrose.
EFFECT: group of inventions provides reduction of immune response and reduction of reactions on region of injections in patients subjected to treatment of Gaucher disease.
37 cl, 9 ex, 40 tbl, 26 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE | 2010 |
|
RU2733466C2 |
| COMPOSITIONS CONTAINING GLUCOCEREBROSIDASE AND ISOFAGOMINE | 2018 |
|
RU2790262C2 |
| METHODS OF TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | 2020 |
|
RU2824599C2 |
| ENZYME REPLACEMENT THERAPY WITH DOSE INCREASE FOR TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY | 2010 |
|
RU2569744C2 |
| CD40L ANTAGONIST AND METHODS OF ITS USE | 2019 |
|
RU2812919C2 |
| ENZYMATIC REPLACEMENT THERAPY WITH DOSE INCREASE FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY | 2010 |
|
RU2731616C2 |
| THERAPEUTIC WAYS FOR TREATING PATIENTS WITH RECOMBINANT ERYTHROPOIETIN OF HIGH ACTIVITY AND DECREASED SIDE EFFECTS | 2001 |
|
RU2282460C2 |
| METHODS AND COMPOSITIONS FOR DELIVERING THERAPEUTIC PROTEIN | 2019 |
|
RU2818779C2 |
| DOSAGE AND REGIMEN FOR TREATING OR PREVENTING C5-RELATED DISEASES BY USING THE ANTI-C5 CROVALIMAB ANTIBODY | 2020 |
|
RU2823427C2 |
| COMPOSITIONS AND METHODS FOR APPLYING PHORBOL ESTERS | 2008 |
|
RU2472511C2 |
